Form 4: Aquestive Therapeutics SVP Acquires Shares and Options, Disposes of Shares for Tax Obligations

Sherry Korczynski, SVP of Sales and Marketing at Aquestive Therapeutics, reports acquisition of shares and options, along with disposition of shares to cover tax obligations.

Summary

• On March 7, 2025, Sherry Korczynski, SVP of Sales and Marketing at Aquestive Therapeutics, acquired 90,000 shares of common stock.
• These shares are represented by restricted stock vesting in three annual installments: 25% on the first and second installments, and 50% on the third.
• Korczynski also acquired 35,000 non-qualified stock options with an exercise price of $2.65, vesting in the same three-year installment schedule.
• Additionally, 5,428 shares were disposed of at $2.65 per share to satisfy tax withholding obligations related to the vesting of previously granted Restricted Stock Units (RSUs).
• Following these transactions, Korczynski directly owns 159,572 shares of common stock and 35,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard executive compensation practices and tax obligation fulfillment. The acquisition of shares and options is mildly positive, suggesting confidence, but the disposal for tax purposes is a neutral event.

Positives

• The acquisition of shares and options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the executive's holdings.

Risks

• The vesting schedule of the restricted stock and options could influence the executive's decisions regarding their holdings and tenure with the company.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders trade in their company's stock. It provides transparency to investors about the transactions of key personnel.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, and restricted stock units.
• Vesting schedules are a common mechanism to incentivize long-term commitment from executives.
• The specific terms of these grants (vesting schedule, exercise price) are generally benchmarked against similar companies in the pharmaceutical industry to attract and retain talent.

Stakeholder Impact

• Shareholders are informed about the transactions of a key executive, providing transparency into insider activity.
• The vesting schedule of the equity grants may incentivize the executive to focus on long-term value creation for the company.

Key Dates